A Novel Biplex Onchocerca volvulus Rapid Diagnostic Test Evaluated Among 3- to 9-Year-Old Children in Maridi, South Sudan

<b>Background</b>: Point-of-care diagnostic tests are essential for confirming <i>Onchocerca volvulus</i> transmission in remote, resource-limited, onchocerciasis-endemic communities. In Maridi, South Sudan, we field-tested a novel "biplex A" rapid diagnostic test (RDT) developed by Drugs & Diagnostics for Tropical Diseases (DDTD), San Diego, California. <b>Methods</b>: In February 2023, children aged 3-9 years were recruited from study sites at different distances from the Maridi Dam, a known blackfly breeding site. <i>O. volvulus</i> antibodies were detected using the DDTD biplex A RDT, which detects antibodies to Ov16 and OvOC3261 at test line 1 and to Ov33.3 and OvOC10469 at test line 2, along with the commercially available Ov16 SD Bioline RDT. Both tests were performed on whole blood obtained via finger prick. The feasibility and acceptability of the DDTD biplex A RDT were assessed, and its results were compared with those of the Ov16 SD Bioline RDT. <b>Results</b>: A total of 239 children participated in the study. The anti-Ov16 seroprevalence detected by the Ov16 SD Bioline RDT was 30.2% (72/239), with the highest prevalence observed in children living closest to the Maridi Dam (<i>p</i> < 0.001). Testing with the DDTD biplex A RDT was determined to be feasible, acceptable, and easy to use in a field setting. The DDTD biplex A RDT test line 1 (anti-Ov16 and anti-OvOC3261) was positive in 35.1% (84/239) of children, while test line 2 (anti-Ov33.3 and anti-OvOC10469) was positive in 18.4% (44/239). Both lines were simultaneously visible in 15.5% (37/239). <b>Conclusions</b>: The DDTD biplex A RDT prototype was user-friendly and practical for field deployment. However, additional research is needed to evaluate its performance relative to the commercially available Ov16 SD Bioline RDT. The high anti-Ov16 seroprevalence that was observed underscores the ongoing <i>O. volvulus</i> transmission near the Maridi Dam. Strengthening the onchocerciasis elimination program in Maridi should be prioritized as a critical public health intervention.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2025-02-26
DOI
https://doi.org/10.3390/diagnostics15050563
Citations
4
Primary Topic
Parasitic Diseases Research and Treatment
Type
article
Field-Weighted Citation Impact
5.58
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Novel Biplex Onchocerca volvulus Rapid Diagnostic Test Evaluated Among 3- to 9-Year-Old Children in Maridi, South Sudan

Yak Yak Bol, Dziedzom K. de Souza, Amber Hadermann, Robert Colebunders et al.
4 citations
Diagnostics
Parasitic Diseases Research and Treatment
5.58
article

A Novel Biplex Onchocerca volvulus Rapid Diagnostic Test Evaluated Among 3- to 9-Year-Old Children in Maridi, South Sudan

Yak Yak Bol, Dziedzom K. de Souza, Amber Hadermann, Robert Colebunders, Luís‐Jorge Amaral, Marco A. Biamonte, Joseph Nelson Siewe Fodjo, Stephen Raimon Jada, Charlotte Lubbers
article en
4 citations

Abstract

<b>Background</b>: Point-of-care diagnostic tests are essential for confirming <i>Onchocerca volvulus</i> transmission in remote, resource-limited, onchocerciasis-endemic communities. In Maridi, South Sudan, we field-tested a novel "biplex A" rapid diagnostic test (RDT) developed by Drugs & Diagnostics for Tropical Diseases (DDTD), San Diego, California. <b>Methods</b>: In February 2023, children aged 3-9 years were recruited from study sites at different distances from the Maridi Dam, a known blackfly breeding site. <i>O. volvulus</i> antibodies were detected using the DDTD biplex A RDT, which detects antibodies to Ov16 and OvOC3261 at test line 1 and to Ov33.3 and OvOC10469 at test line 2, along with the commercially available Ov16 SD Bioline RDT. Both tests were performed on whole blood obtained via finger prick. The feasibility and acceptability of the DDTD biplex A RDT were assessed, and its results were compared with those of the Ov16 SD Bioline RDT. <b>Results</b>: A total of 239 children participated in the study. The anti-Ov16 seroprevalence detected by the Ov16 SD Bioline RDT was 30.2% (72/239), with the highest prevalence observed in children living closest to the Maridi Dam (<i>p</i> < 0.001). Testing with the DDTD biplex A RDT was determined to be feasible, acceptable, and easy to use in a field setting. The DDTD biplex A RDT test line 1 (anti-Ov16 and anti-OvOC3261) was positive in 35.1% (84/239) of children, while test line 2 (anti-Ov33.3 and anti-OvOC10469) was positive in 18.4% (44/239). Both lines were simultaneously visible in 15.5% (37/239). <b>Conclusions</b>: The DDTD biplex A RDT prototype was user-friendly and practical for field deployment. However, additional research is needed to evaluate its performance relative to the commercially available Ov16 SD Bioline RDT. The high anti-Ov16 seroprevalence that was observed underscores the ongoing <i>O. volvulus</i> transmission near the Maridi Dam. Strengthening the onchocerciasis elimination program in Maridi should be prioritized as a critical public health intervention.

DiagnosticsVol. 15(5)
University of Ghana (GH), University of Antwerp (BE), University of Juba (SS), Liverpool School of Tropical Medicine (GB), Drugs & Diagnostics for Tropical Diseases (US), Noguchi Memorial Institute for Medical Research (GH)
Openalex Percentile: Top 5%
Parasitic Diseases Research and Treatment
5.58
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.